On November 17, Isomorphic Labs, the AI drug-discovery company spun out of Google DeepMind, announced a $5 billion Series C round co-led by Greenoaks and Sequoia Capital. It is the largest financing in AI drug discovery this year, and the money is aimed at a decisive turning point: getting AI-designed drug candidates into human clinical trials for the first time.
The round was oversubscribed. New investors include Andreessen Horowitz, Alphabet continued to invest heavily, and all existing backers — Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund — took part. The company did not disclose a valuation; Bloomberg reported in early November that it had been negotiating at a valuation of around $50 billion, but that was only a report from the negotiation stage, not a price. The previous round was a $2.1 billion Series B led by Thrive Capital in May, bringing the two rounds to $7.1 billion combined.
Where the money goes: IsoDDE and the first clinical pipeline
The announcement is specific about the use of funds: keep refining IsoDDE, the company's drug-design engine, advance foundational biology models and systemic-disease research, move internal and partnered drug candidates toward the clinic, and build global AI-led bioengineering infrastructure. Isomorphic Labs grew out of DeepMind's AlphaFold protein-structure prediction work; the engine's idea is to use AI to design new drugs at the molecular level, predict their properties, and then decide which candidates to test. Its partners include Novartis, Eli Lilly and Johnson & Johnson. Founder and CEO Demis Hassabis said in the announcement that the round is meant to accelerate progress, drive the first therapeutic programs toward clinical trials, and deliver tangible impact for patients. Earlier this year he stepped down as CEO of DeepMind to become chairman and focus entirely on Isomorphic Labs.
What the $5 billion is — and is not — betting on
The money is not betting on whether AI can design molecules — after AlphaFold, that is barely disputed — but on whether AI-designed molecules can survive clinical trials and become approved drugs. Isomorphic Labs has no drug in human trials yet, and Hassabis has said the first oncology trials are targeted to start before the end of 2026; the timetable itself is the first test. The valuation is equally open: $50 billion is only a negotiation report, and the real price awaits later disclosure. The capital race in AI drug discovery is heating up too: OpenAI acquired drug-discovery company Orchestra Bio last month, buying the execution side of the R&D process. OpenAI Acquires Orchestra Bio: It's Not Buying Drugs, It's Buying the Busywork of Drug R&D
Three things are worth watching now: whether the first clinical trials start on schedule before the end of the year, which indications the first IsoDDE-designed candidates cover, and when the company discloses its valuation. AI drug discovery has promised for years to reinvent drug R&D; after $5 billion, that story faces the test of clinical trials for the first time.